Sorrento Presents Preliminary Results of STI-2020 Against COVID-19
Shots: The approval is based on P-III KEYNOTE-426 study assessing Keytruda (pembrolizumab, 200mg, q3w up to 24mos.) + Inlyta (axitinib,5mg, bid) vs sunitinib (50mg, qd for 4wks.) in 861 patients in ratio (1:1) who had not received systemic therapy for advanced RCC The P-III KEYNOTE-426 & median 12.8mos. follow up studies result: 47% reduction in […]Read More